GSBS Student Publications


In vitro evidence that commercial influenza vaccines are not similar in their ability to activate human T cell responses

Student Author(s)

James A. Potts

UMMS Affiliation

Center for Infectious Disease and Vaccine Research; Department of Biochemistry and Molecular Pharmacology



Document Type


Medical Subject Headings

Adult; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line; Cytokines; Drug Industry; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza Vaccines; Influenza, Human; Interferon-gamma; *Lymphocyte Activation; Male; Middle Aged; Nucleocapsid Proteins; T-Lymphocytes; Vaccines, Inactivated; Viral Matrix Proteins


Immunology and Infectious Disease | Life Sciences | Medicine and Health Sciences


We evaluated three commercial trivalent inactivated vaccines (TIVs) from the 2007-2008 season in terms of their ability to elicit in vitro T cell responses. T cell-mediated immunity may offer a more cross-reactive vaccine approach for the prevention of pandemic or epidemic influenza. Human cytotoxic T cell lines demonstrated differences in matrix protein 1 and nucleocapsid protein recognition of autologous target cells. Peripheral blood mononuclear cells stimulated with each of the TIVs showed statistically significant differences between the vaccines in the numbers of IFNgamma producing cells activated. These data suggest that TIV vaccines are not similar in their ability to activate human T cell responses.

Rights and Permissions

Citation: Vaccine. 2009 Jan 7;27(2):319-27. Epub 2008 Oct 31. Link to article on publisher's site

DOI of Published Version


Related Resources

Link to Article in PubMed

Journal Title


PubMed ID